Lewallen D G
Mayo Graduate School of Medicine, Mayo Clinic/Mayo Foundation, Rochester, Minnesota, USA.
Instr Course Lect. 1995;44:287-92.
Although heterotopic ossification following total hip arthroplasty is frequently observed radiographically, it fortunately is much less commonly of clinical importance. There are, however, a group of patients that develop significant heterotopic bone formation, which can be symptomatic and, in some cases, can require repeat surgery. Careful surgical technique seems indicated in all patients undergoing total hip arthroplasty to try to reduce the incidence of this problem. Patients who are recognized to be at risk should be treated with prophylaxis. These include patients with active ankylosing spondylitis, skeletal hyperostosis, and prior heterotopic bone formation. Both low-dose radiation and nonsteroidal anti-inflammatories have been shown to be effective. The choice between these two modalities depends on the patient's individual circumstances, the availability of radiotherapy support (including custom shielding for ingrowth components), and the presence of areas of bone grafting and any osteotomies or fractures. Nonsteroidal anti-inflammatories, particularly Indomethacin, are a very acceptable form of prophylaxis and may be preferred in certain patients, including young women of childbearing age. Radiation is preferred in those patients with known GI intolerance to these medications or with a prior history of peptic ulcer disease. Excision of heterotopic bone, if symptomatic, should not be performed before 6 to 12 months and then only once it is clear that the process is mature. Bone scans can be helpful in assessing the maturity of heterotopic bone and can guide the timing of excision. Prophylaxis should be carried out in all patients following excision of heterotopic bone.(ABSTRACT TRUNCATED AT 250 WORDS)
尽管全髋关节置换术后异位骨化在影像学检查中经常可见,但幸运的是,具有临床意义的情况并不常见。然而,有一组患者会出现明显的异位骨形成,这可能会出现症状,在某些情况下还需要再次手术。对于所有接受全髋关节置换术的患者,似乎都应采用精细的手术技术,以尽量降低该问题的发生率。被认定有风险的患者应进行预防治疗。这些患者包括患有活动性强直性脊柱炎、骨质增生症以及既往有异位骨形成的患者。低剂量放疗和非甾体类抗炎药均已被证明有效。这两种方式的选择取决于患者的个体情况、放疗支持的可获得性(包括为植入部件定制屏蔽)以及是否存在骨移植区域和任何截骨术或骨折情况。非甾体类抗炎药,尤其是吲哚美辛,是一种非常可接受的预防方式,在某些患者中可能更受青睐,包括育龄期年轻女性。对于已知对这些药物有胃肠道不耐受或有消化性溃疡病史的患者,放疗更为可取。如果异位骨有症状,在6至12个月之前不应进行切除,且只有在明确病情已成熟后才能进行。骨扫描有助于评估异位骨的成熟度,并可指导切除时机。在切除异位骨后的所有患者中都应进行预防治疗。(摘要截取自250字)